AGTC Genomics Expands Cancer Genomics Sponsorship Program to Deliver Comprehensive, Equitable Precision Cancer Care Across Southeast Asia
- Feb 15
- 4 min read
Kuala Lumpur, Malaysia — In conjunction with World Cancer Day, AGTC Genomics proudly announces the continuation and regional expansion of its PRECiSE Cancer Genomics Sponsorship Program, a Southeast Asia–focused initiative launched in 2024 to close the precision medicine gap in cancer care.
Operating from an ISO 15189 and College of American Pathologists (CAP)–accredited advanced genomics laboratory, AGTC Genomics reaffirms its commitment to delivering international-quality, clinically validated, and affordable genomic testing solutions — locally.
A Program Designed to Close the Precision Gap
Originally initiated in 2024, the PRECiSE Program was created to support cancer patients who lacked access to comprehensive genomic testing due to financial constraints, limited availability, or prolonged overseas referral timelines.
With its 2025 regional expansion, the program now serves patients across Southeast Asia under a structured sponsorship framework — ensuring that molecular diagnostics are integrated early and appropriately in cancer management.
Since its inception, thousands of patients have benefited from access to clinical-grade genomic profiling that directly informed their treatment strategies.
By addressing affordability, local accessibility, and turnaround time, the program tackles one of oncology’s most pressing challenges: inequitable access to precision diagnostics.
Covering the Full Continuum of Precision Oncology
In 2026, the program now integrates the entire cancer care continuum under one coordinated framework:
1️⃣ Early Cancer Detection
Advanced multi-cancer detection strategies designed to identify cancer-associated molecular signals at earlier stages — enabling timely intervention and better-informed clinical pathways.
2️⃣ Comprehensive Gene Profiling
Broad molecular profiling for solid tumors and hematological malignancies, identifying actionable mutations, gene fusions, copy number alterations, and clinically relevant biomarkers aligned with FDA, NCCN, ASCO, and ESMO guidelines.
These insights support targeted therapy selection, immunotherapy stratification, and clinical trial matching.
3️⃣ Minimal Residual Disease (MRD) Monitoring
Highly sensitive circulating tumor DNA (ctDNA) assays to detect microscopic residual disease following treatment, assess recurrence risk, and monitor therapeutic response in real time.
By integrating detection, diagnosis, and monitoring within a unified ecosystem, PRECiSE™ enables oncologists to make informed, evidence-based decisions throughout the patient journey — from suspicion to survivorship.
Real-World Impact: Patient and Clinician Perspectives
Patient 1 — Metastatic Lung Cancer
Mr. A., a 56-year-old non-smoker diagnosed with Stage IV lung adenocarcinoma, initially began chemotherapy due to limited molecular data availability. Through PRECiSE™, comprehensive tumor profiling identified an actionable EGFR mutation.
“I was told chemotherapy was my only option at first. When the genomic report came back, my oncologist switched me to targeted therapy. Within weeks, my symptoms improved significantly. I did not know this testing existed locally — it changed everything for me.”
The molecular finding enabled a shift from generalized cytotoxic therapy to precision-targeted treatment, optimizing both response and tolerability.
Patient 2 — Breast Cancer Survivor Under MRD Monitoring
Ms. L., a 43-year-old breast cancer patient who completed surgery and adjuvant therapy, enrolled in the PRECiSE™ MRD monitoring program.
“After treatment, the biggest fear is recurrence. The MRD blood test gave me reassurance. My oncologist could monitor my cancer at a molecular level — not just through scans. That peace of mind is something I cannot describe.”
By detecting circulating tumor DNA signals with high sensitivity, MRD testing allows clinicians to assess microscopic disease dynamics before clinical relapse becomes visible.
Oncologist 1 — Integrating Molecular Evidence into Daily Practice
Dr. R., a medical oncologist practicing in Kuala Lumpur, highlighted the program’s clinical value:
“Before local comprehensive genomic profiling was available, we sometimes faced delays waiting for overseas results, or patients declined testing due to cost. PRECiSE has changed the way we practice. We now have timely, high-quality molecular reports that guide first-line therapy decisions. It allows us to personalize treatment from the beginning rather than reacting later.”
The program not only enhances clinical decision-making but strengthens confidence in precision oncology as a routine standard of care.
“Cancer patients cannot afford delays, uncertainty, or fragmented testing strategies. Through PRECiSE, we are building an integrated precision oncology ecosystem across Southeast Asia — from early detection to longitudinal monitoring — so that every treatment decision is informed by molecular evidence. Genomics is not just about technology; it is about delivering clarity, enabling timely intervention, and ensuring that precision cancer care is equitably accessible within our community.” said Dr Chee-Onn Leong, Founder and Chief Executive Officer of AGTC Genomics.
Advancing Equity Through Local Excellence
Historically, advanced genomic testing required overseas referral, higher costs, and prolonged turnaround times. By conducting all testing locally within its ISO 15189 and CAP-accredited laboratory, AGTC Genomics ensures:
Internationally benchmarked quality standards
Faster clinical turnaround times
Strengthened regional data sovereignty
More affordable access to clinical-grade testing
In conjunction with World Cancer Day, AGTC Genomics reaffirms its commitment to reducing disparities in oncology care and ensuring that access to precision medicine is not limited by geography or socioeconomic status.
Continuing the Mission
With its 2026 Southeast Asia expansion, the PRECiSE sponsorship program stands as a regional platform for equitable precision oncology — bridging technology, clinical practice, and patient access.
Patients are encouraged to speak with their oncologists to learn more about the AGTC Genomics PRECiSE Program and how it may support their cancer care journey.
Comments